BioNTech’s €16.8 Billion Reserve Can’t Mask the Pain of Its Oncology Pivot as ASCO Data Nears
Published on 05/18/2026 at 13:33 | Redaktion boerse-global.de
BioNTech’s transformation from pandemic-era vaccine champion to oncology contender is proving expensive — and investors are watching the meter tick. The Mainz-based biotech posted a net loss of €531.9 million in the first quarter, as research and development spending surged past $650 million (roughly €600 million). Revenue from the COVID-19 vaccine franchise, now seasonal and shrinking, came in at €118.1 million, underscoring how far the company has moved from its former cash cow.
The stock reflects the market’s caution. At around €76, the shares have shed more than 12% over the past month and trade about 12% below their 200-day moving average. The 52-week high of €101.90, set last summer, looks distant. The market is pricing in execution risk for a pipeline that has yet to deliver a commercial cancer product.
To bridge that gap, BioNTech is strengthening its governance. At the annual general meeting — which represented 92% of total share capital — shareholders approved expanding the supervisory board from six to eight seats. The new members are Prof. Iris Löw-Friedrich, whose background spans medical innovation and commercial launch expertise, and Susanne Schaffert, a seasoned oncology specialist already serving on the board of Merck KGaA. Existing supervisors Helmut Jeggle, Prof. Anja Morawietz, and Prof. Rudolf Staudigl were re-elected, with Jeggle staying on as chairman.
Should investors sell immediately? Or is it worth buying BioNTech?
The board revamp is no cosmetic exercise. As BioNTech’s late-stage oncology candidates near potential market entries, the company needs experience in pricing, reimbursement, and sales — areas where the new appointees add direct value. The timing aligns with a pipeline that is rapidly maturing. BioNTech now runs more than 25 clinical studies in mid-to-late stages, spanning 17 programs. Management expects to have 15 Phase 3 trials underway by the end of 2026, with seven late-stage data readouts due this year alone.
The most immediate catalyst is pumitamig, a bispecific immune modulator. For this candidate alone, five additional registrational studies were initiated in 2026, targeting indications including gastric cancer and non-small cell lung cancer. A pivotal moment comes on May 29 at the ASCO congress, where BioNTech will unveil Phase 2 data from the ROSETTA-Lung-02 trial. There, pumitamig will be compared head-to-head against pembrolizumab (Keytruda), the current standard of care in lung cancer immunotherapy. A strong showing could fundamentally reshape how analysts view the pipeline’s commercial potential.
Financially, BioNTech is well-armed. The company held €16.8 billion in cash, cash equivalents, and securities at the end of March, giving it ample runway for expensive late-stage development. It also has an active American depositary share buyback program of up to $1 billion, running through May 6, 2027, primarily intended to offset share-based compensation. In a further move that raised some eyebrows, shareholders authorized a capital increase of up to 50% of existing share capital. Management framed it not as an emergency measure but as strategic firepower for potential acquisitions or partnerships — a signal that the company is open to using its balance sheet to accelerate the oncology push.
For the full year 2026, management maintains its revenue guidance of €2.0 billion to €2.3 billion, a range largely supported by the remaining vaccine business. Until the oncology pipeline delivers, BioNTech remains a story of high investment, deep losses, and a stock waiting for a data-driven inflection point. The ASCO presentation later this month could be the moment that begins to change the narrative — or confirms the market’s skepticism.
Ad
BioNTech Stock: New Analysis - 18 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
